Definition and epidemiology
Substance use disorder (SUD) is defined by DSM-5 as a problematic pattern of substance use leading to clinically significant impairment or distress, manifested by at least 2 of 11 criteria within a 12-month period. ICD-10 retains separate codes for harmful use and dependence syndrome, coded by substance (F10 alcohol, F11 opioids, F12 cannabinoids, F13 sedatives/hypnotics, F14 cocaine, F15 other stimulants, F16 hallucinogens, F17 tobacco, F19 multiple/other substances).
- Lifetime prevalence of any SUD is roughly 10-15% in the general population, higher in certain subpopulations.
- Alcohol and nicotine remain the most commonly used legal substances; opioids and stimulants drive much of the morbidity/mortality burden.
- Onset typically occurs in adolescence or young adulthood; earlier first use correlates with higher lifetime risk.
- Men are affected more often than women for most substances, though the gap is narrowing.
- Comorbid psychiatric illness (depression, anxiety, PTSD, bipolar disorder, ADHD) is present in a large proportion of patients ("dual diagnosis").
- DSM-5 merged abuse and dependence into one spectrum disorder (mild/moderate/severe based on criteria count)
- Alcohol and benzodiazepine withdrawal can be fatal (seizures, delirium tremens); opioid withdrawal is miserable but not life-threatening and does not cause seizures
- Always give thiamine before glucose in suspected alcohol use disorder to prevent precipitating Wernicke encephalopathy
- Opioid overdose triad: miosis, respiratory depression, coma - treat with naloxone
- Buprenorphine and methadone (opioid agonist therapy) are first-line for opioid use disorder per WHO guidance
- No approved pharmacotherapy exists for stimulant or cannabis use disorder - treatment is behavioral
- CAGE and AUDIT are the classic screening tools for alcohol use disorder
- Naltrexone requires complete opioid detoxification first, or it precipitates acute withdrawal
Etiology and risk factors
SUD arises from an interaction of genetic vulnerability, neurobiological changes, and environmental exposure.
Risk factors
- Family history of addiction (genetic heritability estimated at 40-60% for alcohol use disorder)
- Early age of first use
- Co-occurring mental illness
- Childhood trauma, abuse, or neglect
- Peer substance use and social/environmental availability
- Chronic pain with long-term opioid prescribing
- Low socioeconomic status, unemployment, unstable housing
- Impulsivity and certain personality traits (sensation-seeking)
No single gene is causative; risk is polygenic and substantially modified by environment (gene-environment interaction).
Pathophysiology
Nearly all addictive substances converge on the mesolimbic dopamine pathway (ventral tegmental area to nucleus accumbens), producing reward and reinforcement.
- Acute use triggers supraphysiologic dopamine release, reinforcing drug-seeking behavior.
- Chronic use produces neuroadaptation: downregulation of dopamine receptors and reduced baseline reward sensitivity, driving tolerance and anhedonia during abstinence.
- The prefrontal cortex, responsible for inhibitory control and judgment, shows reduced activity, impairing the ability to resist cravings.
- Withdrawal syndromes reflect rebound hyperactivity of systems that were chronically suppressed by the substance (e.g., CNS/autonomic hyperactivity in alcohol and benzodiazepine withdrawal, due to GABA receptor downregulation and glutamate upregulation).
- Opioids act on mu-opioid receptors; chronic use causes receptor downregulation. Opioid withdrawal does not typically cause seizures; it presents with autonomic hyperactivity (rhinorrhea, diarrhea, piloerection, myalgia) and is not life-threatening, in contrast to alcohol/benzodiazepine withdrawal, which can cause seizures and be fatal.
- Stimulants (cocaine, amphetamines) block dopamine/norepinephrine reuptake, causing acute sympathetic surge and, with chronic use, dopamine depletion contributing to the post-use crash.
Clinical features
DSM-5 criteria (≥2 of 11 in 12 months)
- Using more or longer than intended
- Persistent desire or unsuccessful attempts to cut down
- Great deal of time spent obtaining/using/recovering
- Craving
- Failure to fulfill major role obligations
- Continued use despite social/interpersonal problems
- Giving up important activities
- Use in physically hazardous situations
- Continued use despite physical/psychological harm
- Tolerance
- Withdrawal
Severity: mild (2-3 criteria), moderate (4-5), severe (6+).
Intoxication and withdrawal patterns
| Substance | Intoxication | Withdrawal |
|---|---|---|
| Alcohol | Disinhibition, slurred speech, ataxia | Tremor, seizures, delirium tremens (can be fatal) |
| Opioids | Miosis, sedation, respiratory depression | Rhinorrhea, diarrhea, piloerection, myalgia (not fatal, no seizures) |
| Benzodiazepines | Sedation, ataxia | Anxiety, seizures (can be fatal) |
| Cocaine/stimulants | Euphoria, tachycardia, hypertension, mydriasis | Dysphoria, fatigue, hypersomnia ("crash") |
| Cannabis | Euphoria, conjunctival injection, increased appetite | Irritability, insomnia, decreased appetite (mild) |
| Opioid overdose triad | Miosis, respiratory depression, coma | — |
Diagnosis
Diagnosis is primarily clinical, based on history and DSM-5 criteria, supported by screening tools and laboratory confirmation.
Screening tools
- CAGE questionnaire (Cut down, Annoyed, Guilty, Eye-opener) for alcohol
- AUDIT (Alcohol Use Disorders Identification Test) - more sensitive, used widely
- DAST (Drug Abuse Screening Test) for other substances
- CRAFFT for adolescents
Laboratory and ancillary testing
- Urine toxicology screen (detects recent use; limited window, false positives/negatives possible)
- Blood alcohol concentration
- Liver function tests, GGT, elevated MCV in chronic alcohol use
- Hair/nail testing for longer-term use history (less commonly used clinically)
History should assess quantity, frequency, duration, prior quit attempts, withdrawal history, and functional impact across social, occupational, and legal domains.
Differential diagnosis
- Primary psychiatric disorders (bipolar disorder, major depression, anxiety disorders) presenting with mood/behavioral symptoms mimicking intoxication or withdrawal
- Delirium from other medical causes (infection, metabolic derangement) versus substance-induced delirium
- Primary psychotic disorders versus substance-induced psychosis
- Medication side effects mimicking intoxication (e.g., sedating medications)
- Personality disorders with impulsive behavior patterns
- Behavioral addictions (gambling disorder) - share overlapping reward pathway features without a substance
Management
Management combines acute stabilization (intoxication/withdrawal), relapse prevention pharmacotherapy, and psychosocial treatment. International guidelines (WHO, APA, NICE) agree on a biopsychosocial approach; specific agents vary slightly by region.
Acute management
- Alcohol withdrawal: benzodiazepines (e.g., diazepam, lorazepam, chlordiazepoxide) using symptom-triggered protocols (CIWA-Ar scale); thiamine before glucose to prevent Wernicke encephalopathy
- Opioid overdose: naloxone
- Opioid withdrawal: supportive care, alpha-2 agonists (clonidine), or initiation of agonist therapy
- Stimulant intoxication: supportive care, benzodiazepines for agitation; no specific antidote
Relapse prevention / maintenance pharmacotherapy
- Alcohol use disorder: naltrexone, acamprosate, or disulfiram
- Opioid use disorder: methadone, buprenorphine (opioid agonist therapy, first-line per WHO/SAMHSA), or naltrexone (requires full detoxification first)
- Tobacco use disorder: varenicline, bupropion, nicotine replacement therapy
- No FDA/EMA-approved pharmacotherapy exists for stimulant or cannabis use disorder; management is primarily behavioral
Psychosocial treatment
- Cognitive behavioral therapy
- Motivational interviewing / motivational enhancement therapy
- Contingency management (particularly effective for stimulant use disorder)
- 12-step facilitation and mutual support groups (Alcoholics Anonymous, Narcotics Anonymous)
- Treatment of comorbid psychiatric illness is essential and improves outcomes
Harm reduction strategies (needle exchange programs, supervised consumption sites, naloxone distribution) are increasingly endorsed by WHO and many national guidelines, particularly for opioid use disorder.
Complications and prognosis
- Overdose and death (especially opioids and polysubstance use)
- Infectious complications from injection use: HIV, hepatitis B/C, infective endocarditis, skin/soft tissue infections
- Organ damage: cirrhosis and pancreatitis (alcohol), cardiomyopathy (alcohol, stimulants), cognitive impairment
- Psychiatric comorbidity: increased suicide risk, worsening of underlying mood/psychotic disorders
- Social consequences: unemployment, incarceration, family/relationship breakdown, homelessness
- Fetal effects when used in pregnancy (e.g., fetal alcohol syndrome, neonatal opioid withdrawal syndrome)
SUD is a chronic relapsing condition; relapse rates are comparable to other chronic illnesses like hypertension and diabetes. Long-term engagement in treatment, social support, and management of comorbid psychiatric disease improve outcomes substantially.
CAGE for alcohol screening: Cut down, Annoyed, Guilty, Eye-opener
Practice questions
1. A 45-year-old man with a history of heavy daily alcohol use is admitted for elective surgery. Approximately 48 hours after his last drink, he develops fever, tachycardia, severe tremor, visual hallucinations, and confusion. Which of the following is the most appropriate immediate management?
2. A 28-year-old woman presents with pinpoint pupils, decreased respiratory rate, and depressed level of consciousness after a suspected overdose. Which medication should be administered immediately?
3. A 34-year-old man with opioid use disorder wants to start maintenance pharmacotherapy. He has been abstinent from opioids for 10 days and wants a treatment option that does not carry risk of diversion or overdose if misused. Which medication is most appropriate?
Frequently asked questions
What causes substance use disorder?
Substance use disorder results from a combination of genetic vulnerability, neurobiological changes in brain reward circuits, and environmental factors. Repeated exposure to addictive substances alters dopamine signaling in the mesolimbic pathway, reinforcing use and weakening the prefrontal cortex's ability to control impulses. Risk is increased by family history, early first use, trauma, co-occurring mental illness, and social environment.
What are the first signs of substance use disorder?
Early signs include using more of a substance or for longer than intended, unsuccessful attempts to cut down, cravings, and spending increasing time obtaining or recovering from use. Functional changes often follow, such as missing work or school, neglecting relationships or hobbies, and continuing use despite knowing it is causing problems. Tolerance (needing more for the same effect) is also an early marker.
How is substance use disorder diagnosed?
Diagnosis is clinical, using DSM-5 criteria that require at least 2 of 11 symptoms within a 12-month period, covering impaired control, social impairment, risky use, and pharmacological criteria (tolerance, withdrawal). Screening tools like CAGE, AUDIT, or DAST help identify at-risk patients, and urine toxicology or blood tests can confirm recent use but do not establish the diagnosis alone.
Is substance use disorder curable?
Substance use disorder is generally considered a chronic, relapsing condition rather than one that is simply cured, similar to diabetes or hypertension. However, long-term remission and functional recovery are very achievable with sustained treatment, including behavioral therapy, medications where available, and ongoing social support. Many people achieve lasting recovery, though relapse during the process is common and not a sign of treatment failure.
Substance abuse vs substance dependence - what is the difference?
These older DSM-IV terms are no longer used separately; DSM-5 combined them into a single diagnosis called substance use disorder, graded by severity. Historically, 'abuse' referred to harmful use without physical dependence, while 'dependence' included tolerance and withdrawal. The change reflects evidence that these represented a continuum of severity rather than two distinct conditions.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: F19
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.